Nexalin Technology
Non-invasive brain-stimulation systems for clinical and physician-supervised home care.
Something off on this page? Send us feedback.
Profile
Sells and develops non-invasive electrical brain-stimulation systems, with current revenue from international devices, equipment, licensing, treatments and consumables. Its platform spans legacy clinical systems, in-clinic SYNC and planned physician-supervised HALO home care, while next-generation U.S. commercialization remains subject to clinical work and FDA authorization.
Designs non-invasive electrical brain-stimulation products across legacy clinical systems, the in-clinic SYNC device and the planned HALO home headset. Current revenue combines international device and equipment shipments with licensing, treatment and recurring consumables; legacy U.S. placements continue to generate support and service activity.
Commercial activity is China-led, alongside smaller U.S. legacy revenue and approvals reported in several overseas markets. A lean network of partners, clinical contractors, distributors and the China joint venture supports research, manufacturing, regulatory work and commercialization. U.S. sales of next-generation systems depend on clinical evidence and FDA authorization, while China registrations depend on its joint-venture partner.
Company facts
Categories
Key statistics
Year to date −56.3% · Average volume (30d) 196.2K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.10 | −$0.11 | −10.0% | $90.0K | $12.2K | −86.5% | −0.70% |
| May 8, 2026Q1 FY26 | −$0.11 | −$0.11 | 0.0% | $15.0K | $15.0K | −0.3% | −3.49% |
| Mar 25, 2026Q4 FY25 | −$0.12 | −$0.13 | −8.3% | $80.0K | $172.0K | +115.0% | −5.10% |
| Nov 14, 2025Q3 FY25 | −$0.12 | −$0.13 | −8.3% | $40.0K | $18.1K | −54.6% | 0.00% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $41.0K | $70.6K | $18.1K | $171.9K | $15.0K | $12.2K | |
| Gross profit | $27.5K | $47.8K | $14.2K | $150.9K | −$496.3K | $8.9K | |
| Operating income | −$2.0M | −$1.6M | −$2.3M | −$2.4M | −$2.1M | −$2.2M | |
| Net income | −$2.0M | −$1.6M | −$2.3M | −$2.4M | −$2.1M | −$2.2M | |
| Diluted EPS | −$0.15 | −$0.10 | −$0.13 | −$0.13 | −$0.11 | −$0.11 | |
| Gross margin | 66.9% | 67.6% | 78.2% | 87.8% | -3,319.5% | 73.2% | |
| Operating margin | -4,903.6% | -2,296.2% | -12,924.3% | -1,403.9% | -14,179.9% | -18,479.7% |
Fiscal years (4-quarter sums)FY21 $144.1K · FY22 $1.3M · FY23 $110.7K · FY24 $168.7K · FY25 $301.6K
Revenue by product · Q4 FY25
Revenue by geography · Q1 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.0M · Total debt $0 · Total assets $3.0M · Shareholders' equity $1.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 22.01M · Float 17.81M · 80.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Alumni Capital LP | 2.49M | 9.99% | 13G | Aug 27, 2026 |
| Osser Leonard · 10 percent owner | 1.62M | 7.35% | Form 4 | Sep 30, 2025 |
| Peak6 LLC | 384.5K | 1.75% | 13F | May 14, 2026 |
| Ben Hu · director | 377.1K | 1.71% | Form 4 | Sep 30, 2025 |
| Geode Capital Management, LLC | 247.0K | 1.12% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 10, 2025 | Marilyn Elson | 10 percent owner | −23,150 | $4.15 |
Peers
- Neuronetics
Leading U.S. TMS rival for clinic-based depression care.
- BrainsWay (ADR)
Deep TMS competes for clinic-based, non-drug depression treatment.
- LivaNova
VNS Therapy competes for treatment-resistant depression patients.
- Johnson & Johnson
SPRAVATO is a pharmacologic alternative in treatment-resistant depression.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nexalin Technology | $0.2679 | +5.81% | $5.5M | — | — | 25.3 | −82.8% |
| Neuronetics | $2.97 | +0.89% | $204.6M | — | — | 1.3 | +9.1% |
| BrainsWay (ADR) | $14.30 | +0.85% | $560.9M | 32.5 | 35.4 | 9.0 | +35.4% |
| LivaNova | $80.32 | −0.02% | $4.41B | 23.7 | 18.2 | 3.0 | +10.8% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Median | 31.1 | 22.4 | 4.8 | +9.9% |